Anti-MCT1 Rabbit Monoclonal Antibody

Overview

This product is an anti-SLC16A1 antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone 20S76; isotype IgG; reactivity: Human. Reported application contexts include WB, IHC (as provided in the source record). Boster Bio Anti-MCT1 Rabbit Monoclonal Antibody catalog # M02240. Tested in IHC, WB application. This antibody reacts with Human.

Key elements and design rationale

• Target: SLC16A1 (T-cell surface glycoprotein CD8 alpha chain).
• Antibody format: Monoclonal; clone 20S76; isotype IgG.
• Host: Rabbit.
• Species reactivity: Human (confirm in your model system with appropriate controls).

This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.

Biological background

SLC16A1 (protein: Lysosome-associated membrane glycoprotein 2 (Lamp2)) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Identifies cytotoxic/suppressor T-cells that interact with MHC class I bearing targets. CD8 is thought to play a role in the process of T-cell mediated killing. CD8 alpha chains binds to class I MHC molecules alpha-3 domains. Reported cellular localization context: Isoform 1: Cell membrane; Single-pass type I membrane protein. Tissue expression notes (as provided): Expressed at high levels in adult kidney, skeletal and placenta tissues and at very low levels in adult heart, lung and brain tissues. .

Research relevance and current trends

• Research context keywords from the source record include: Cardiovascular,Cofactors, Vitamins/Minerals,Cytoskeleton/ECM,ECM Enzymes,Extracellular Matrix,Metabolism,Pathways and Processes,Signal Transduction,Vitamins/Minerals.
• Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
• Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.

Common research applications

• Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
• Immunohistochemistry (IHC): evaluate spatial distribution of target-positive staining in tissue architecture.

Workflow ideas (metafield): Validate SLC16A1 antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect SLC16A1 expression by Western blot in cell or tissue lysates, Detect SLC16A1 in FFPE tissue sections by immunohistochemistry

Notes for experimental interpretation

• Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
• Apparent molecular weight may vary by sample type and processing (observed MW: 75 kDa; calculated MW: 25729 MW).
• Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.

Additional product details (from the source record)

• Molecular weight (observed): 75 kDa
• Cellular localization (provided): Isoform 1: Cell membrane; Single-pass type I membrane protein.
• Tissue details (provided): Expressed at high levels in adult kidney, skeletal and placenta tissues and at very low levels in adult heart, lung and brain tissues. .

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.